Monissa Solberg
Psychiatry · Riverside, RINPI 1164658027
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 765 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 765 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Neurocrine Biosciences, Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Vanda Pharmaceuticals Inc.$925
- Alkermes, Inc.$923
- plus $6K from 18 others
What the payments were for
- Food & beverage$14,56798%
- Education$2632%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 182 | $3,046 |
| Neurocrine Biosciences, Inc. | 58 | $1,387 |
| Supernus Pharmaceuticals, Inc. | 44 | $1,267 |
| Takeda Pharmaceuticals U.S.A., Inc. | 73 | $1,051 |
| Vanda Pharmaceuticals Inc. | 33 | $925 |
| Alkermes, Inc. | 51 | $923 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 49 | $878 |
| Otsuka America Pharmaceutical, Inc. | 42 | $812 |
| Teva Pharmaceuticals USA, Inc. | 44 | $811 |
| Lundbeck LLC | 32 | $704 |
| Axsome Therapeutics, Inc. | 29 | $623 |
| Corium, LLC | 27 | $465 |
| Sunovion Pharmaceuticals Inc. | 23 | $414 |
| Ironshore Pharmaceuticals Inc. | 20 | $390 |
| E.r. Squibb & Sons, L.L.C. | 14 | $248 |
| Johnson & Johnson | 10 | $247 |
| Bausch Health US, LLC | 9 | $176 |
| Collegium Pharmaceutical, Inc. | 9 | $156 |
| Neos Therapeutics, LP | 6 | $127 |
| Idorsia Pharmaceuticals US Inc | 5 | $85 |
| Almatica Pharma LLC | 2 | $41 |
| Sage Therapeutics, LLC | 1 | $20 |
| Neuronetics, Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,830 in reported general payments places this provider in the 95th percentile of 209 psychiatry providers in Rhode Island.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 15 | $100,985 |
| SpravatoEsketamine Hcl | 53 | $63,258 |
| LybalviOlanzapine/Samidorphan Malate | 17 | $29,678 |
| TrintellixVortioxetine Hydrobromide | 31 | $25,733 |
| RexultiBrexpiprazole | 14 | $21,096 |
| CaplytaLumateperone Tosylate | 12 | $20,609 |
| QelbreeViloxazine Hcl | 13 | $12,928 |
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,107 |
| AzstarysSerdexmethylphen/Dexmethylphen | 12 | $4,778 |
| Vilazodone Hcl | 29 | $4,258 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 137 | $4,189 |
| Lurasidone Hcl | 11 | $4,018 |
| Clonazepam | 313 | $3,074 |
| Clozapine | 24 | $3,047 |
| Gabapentin | 105 | $2,835 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $811 | $100,98515 claims |
| Johnson & JohnsonSpravato | $247 | $63,25853 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,051 | $30,84045 claims |
| Alkermes, Inc.Lybalvi | $923 | $29,67817 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $812 | $21,09614 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $878 | $20,60912 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $1,267 | $12,92813 claims |
| Corium, LLCAzstarys | $465 | $4,77812 claims |
| Almatica Pharma LLCSertraline Hcl | $41 | $69866 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 209 psychiatry providers in Rhode Island.
Other psychiatry in Riverside
- Lisa FrappierRiverside$3K
- Richard MillerCranston$864K
- Warren OngWarwick$807K
- James GreerProvidence$780K
- Mark ZimmermanCranston$225K
- Liliya KoyfmanWarwick$110K
- Linda CarpenterProvidence$37K
- Gene JacobsCranston$27K
- Terrie MailhotWarwick$26K
- Ethan KischWarwick$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.